Skip to main content
. 2018 Jun 15;23:412–421. doi: 10.12659/AOT.909212

Table 3.

Change in eGFR, CRP, lipids, and cytokine levels.

Baseline, median (IQR) Post-transplantation, median (IQR) P
eGFR, ml/min/1.73 m2 5.38 (4.29, 6.75) 71.97 (55.08, 78.04) 0.005
CRP, mg/L 0.42 (0.34, 0.50) 0.55 (0.37, 1.32) 0.24
TC, mg/dL 167.0 (146.0, 239.0) 237.0 (217.25, 293.0) 0.02
Triglyceride, mg/dL 132.50 (95.25, 220.50) 162.0 (129.0, 204.75) 0.72
HDL-cholesterol, mg/dL 36.50 (27.0, 53.50) 55.0 (41.50, 75.50) 0.047
LDL-cholesterol, mg/dL 100.0 (88.50, 167.0) 142.50 (133.75, 168.25) 0.074
TNF-α, pg/mL 14.95 (13.87, 18.25) 13.42 (11.62, 16.38) 0.45
 Rituximab-untreated group (n=5) 15.13 (13.60, 18.19) 12.07 (11.16, 13.87) 0.04
 Rituximab-treated group (n=5) 14.76 (13.62, 18.55) 15.41 (12.86, 25.00) 0.50
IL-6, pg/mL 3.50 (2.67, 6.04) 15.49 (4.12, 320.09) 0.03
 Rituximab-untreated group (n=5) 3.60 (2.88, 6.18) 5.55 (3.50, 143.01) 0.50
 Rituximab-treated group (n=5) 3.16 (2.63, 4.95) 23.33 (5.94, 655.10) 0.04
PAI-1, ng/mL 1.25 (0.94, 1.47) 3.57 (2.59, 4.56) 0.005
 Rituximab-untreated group (n=5) 1.20 (0.91, 1.41) 4.13 (2.44, 4.65) 0.04
 Rituximab-treated group (n=5) 1.29 (0.68, 1.72) 3.10 (2.43, 4.43) 0.04
Endothelin-1, pg/mL 297.25 (253.35, 395.23) 334.85 (280.88, 423.25) 0.51
 Rituximab-untreated group (n=5) 302.20 (214.90, 377.30) 371.30 (257.85, 441.60) 0.23
 Rituximab-treated group (n=5) 292.30 (271.35, 410.05) 311.40 (259.55, 411.10) 0.69

IQR – interquartile range; eGFR – estimated glomerular filtration rate; CRP – C-reactive protein; TC – total cholesterol; HDL-C – high-density lipoprotein-cholesterol; LDL-C – low-density lipoprotein-cholesterol; TNF-α – tumor necrosis factor-alpha; IL-6 – interleukin-6; PAI-I – plasminogen activator inhibitor-1.